Intelligence Feed event · Policy · 2026-09-09

    CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M

    Question

    CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M

    Direct answer

    CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/crispr-therapeutics-gains-fda-pediatric-approval-for-casgevy-as-sales-hit-76m-abebe7

    POLICY
    CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
    CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.
    CRSPVRTX
    Impact
    73
    SEP 9
    SIG
    85%
    CRSPVRTX
    CRISPR Therapeutics Gains FDA Pediatric Approval for Casgevy as Sales Hit $76M
    CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.
    → FDA label expansion into pediatric populations widens the addressable patient pool, directly increasing Casgevy commercial uptake and partnership revenue for CRSP and VRTX.
    Impact
    CRISPR Therapeutics secured an expanded FDA label for Casgevy to treat pediatric patients aged 2 and older, broadening the total addressable commercial market for the gene-editing therapy. The regulatory milestone coincides with accelerating commercial execution, as Casgevy sales advanced 78% quarter-over-quarter to reach $76 million in the second quarter.
    Affected
    CRSPVRTX
    Transmission
    FDA label expansion into pediatric populations widens the addressable patient pool, directly increasing Casgevy commercial uptake and partnership revenue for CRSP and VRTX.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CRSPexpanded addressable patient population driving commercial product revenue growthUp1-3mFDA approved pediatric label expansion for Casgevy as Q2 sales surged 78% quarter-over-quarter to $76M.
    VRTXco-development profit share revenue expansion from Casgevy commercializationUp1-3mVertex is the primary commercialization partner for Casgevy alongside CRISPR Therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    VRTXUpdisagreed521.12 2026-09-09-1.26%-1.51%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month